gdc

FDA News

FDA Approves First Direct-to-Consumer Genetic Test for 3 Types of BRCA Mutations in Men and Women
Cancer ScreeningFDA NewsNewsworthy
This first-ever direct-to-consumer genetic test can provide information on potential risks to individuals who may not have access to genetic screening, but the information may be misleading without feedback from experts.
Stivarga and Opdivo Newest Treatments for Liver Cancer
FDA NewsLiver CancerNewsworthy
In 2017, the FDA approved two new treatments for patients with hepatocellular carcinoma (HCC), Stivarga and Opdivo. Read about these new treatments for liver cancer.
Alecensa a New First-Line Treatment for Lung Cancer with ALK Mutation
FDA NewsLung CancerNewsworthy
In November 2017, the FDA approved Alecensa for the treatment of all patients with metastatic non–small-cell lung cancer (NSCLC) and ALK mutation.
Calquence Newest Treatment Approved for Mantle-Cell Lymphoma
FDA NewsLymphomaNewsworthy
In October 2017, the FDA accelerated the approval of Calquence for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy.
Verzenio a New Targeted Therapy Approved for Metastatic Breast Cancer
Breast CancerFDA NewsNewsworthy
Read about Verzenio, which was approved by the FDA in 2017, in combination with fulvestrant, for treatment of women with HR-positive, HER2-positive, HER2-negative advanced, or metastatic breast cancer that progressed after endocrine therapy.
Lynparza Approved as Maintenance Treatment for Ovarian Cancer
FDA NewsNewsworthyOvarian Cancer
In August 2017, the FDA approved Lynparza tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a response to platinum-based chemotherapy.
Page 1 of 3
Results 1 - 10 of 29

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country